
    
      This is a single-arm, open label, single institution, compassionate study which will enroll
      patients who are marginally engrafted and transfusion and/or growth factors dependent after
      allogeneic hematopoietic stem cell transplant (HSCT) regardless of the underlying disease for
      which the transplant was performed. Study subjects will receive a "booster" infusion of CD34+
      cell selected and T-cell depleted G-CSF mobilized apheresis product from the original stem
      cell donor in order to improve engraftment. The "booster" infusion will be administered
      without prior conditioning.
    
  